Kazia Therapeutics Ltd ADR Asset Resilience Ratio
Kazia Therapeutics Ltd ADR asset resilience ratio. Kazia Therapeutics Ltd ADR (KZIA) has an Asset Resilience Ratio of 0.00% as of December 2019. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Kazia Therapeutics Ltd ADR fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Kazia Therapeutics Ltd ADR (2006–2019)
Asset resilience ratio of Kazia Therapeutics Ltd ADR from 2006 to 2019. This chart shows how Kazia Therapeutics Ltd ADR's Asset Resilience Ratio has changed over time. Read KZIA current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Kazia Therapeutics Ltd ADR's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see KZIA current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Kazia Therapeutics Ltd ADR maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Kazia Therapeutics Ltd ADR Industry Peers by Asset Resilience Ratio
Compare Kazia Therapeutics Ltd ADR's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Kazia Therapeutics Ltd ADR Asset Resilience Ratio by Year (2006–2019)
Kazia Therapeutics Ltd ADR asset resilience ratio by year from 2006 to 2019. The table below shows the annual Asset Resilience Ratio data for Kazia Therapeutics Ltd ADR.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2019-06-30 | 0.00% | $0.00 | $21.18 Million | -- |
| 2018-06-30 | 0.00% | $0.00 | $28.18 Million | -- |
| 2017-06-30 | 0.00% | $0.00 | $35.91 Million | -- |
| 2016-06-30 | 0.00% | $0.00 | $35.52 Million | -- |
| 2015-06-30 | 0.00% | $0.00 | $46.14 Million | -- |
| 2014-06-30 | 0.00% | $0.00 | $4.66 Million | -- |
| 2012-06-30 | 2.85% | $256.00K | $8.98 Million | +0.74pp |
| 2011-06-30 | 2.11% | $268.00K | $12.73 Million | -2.29pp |
| 2010-06-30 | 4.40% | $848.00K | $19.29 Million | +2.27pp |
| 2009-06-30 | 2.13% | $806.00K | $37.84 Million | -12.56pp |
| 2008-06-30 | 14.69% | $6.37 Million | $43.38 Million | -3.16pp |
| 2006-06-30 | 17.85% | $9.13 Million | $51.11 Million | -- |
About Kazia Therapeutics Ltd ADR
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase I… Read more